<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PEN</journal-id>
<journal-id journal-id-type="hwp">sppen</journal-id>
<journal-id journal-id-type="nlm-ta">JPEN J Parenter Enteral Nutr</journal-id>
<journal-title>Journal of Parenteral and Enteral Nutrition</journal-title>
<issn pub-type="ppub">0148-6071</issn>
<issn pub-type="epub">1941-2444</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0148607112463074</article-id>
<article-id pub-id-type="publisher-id">10.1177_0148607112463074</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Communications</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Prescription of Trace Elements in Adults on Home Parenteral Nutrition</article-title>
<subtitle>Current Practice Based on the Canadian Home Parenteral Nutrition Registry</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Abdalian</surname><given-names>R.</given-names></name>
<degrees>MD, CM</degrees>
<xref ref-type="aff" rid="aff1-0148607112463074">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Fernandes</surname><given-names>G.</given-names></name>
<degrees>BSc</degrees>
<xref ref-type="aff" rid="aff2-0148607112463074">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Duerksen</surname><given-names>D.</given-names></name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="aff3-0148607112463074">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jeejeebhoy</surname><given-names>K. N.</given-names></name>
<degrees>MD, FRCPC, PhD</degrees>
<xref ref-type="aff" rid="aff4-0148607112463074">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Whittaker</surname><given-names>S.</given-names></name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="aff5-0148607112463074">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gramlich</surname><given-names>L.</given-names></name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="aff6-0148607112463074">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Allard</surname><given-names>J. P.</given-names></name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="aff2-0148607112463074">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0148607112463074"><label>1</label>North York General Hospital, Toronto, Ontario, Canada</aff>
<aff id="aff2-0148607112463074"><label>2</label>Department of Medicine, University Health Network, Toronto, Ontario, Canada</aff>
<aff id="aff3-0148607112463074"><label>3</label>St Boniface Hospital, University of Manitoba, Winnipeg, Manitoba, Canada</aff>
<aff id="aff4-0148607112463074"><label>4</label>St Michael’s Hospital, Toronto, Ontario, Canada</aff>
<aff id="aff5-0148607112463074"><label>5</label>University of British Columbia, Vancouver, British Columbia, Canada</aff>
<aff id="aff6-0148607112463074"><label>6</label>University of Alberta, Edmonton, Alberta, Canada</aff>
<author-notes>
<corresp id="corresp1-0148607112463074">Johane P. Allard, MD, FRCPC, Department of Medicine, University Health Network, 585 University Avenue, 9N-973, Toronto, ON M5G 2C4, Canada. Email: <email>Dr.Johane.Allard@uhn.on.ca</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2013</year>
</pub-date>
<volume>37</volume>
<issue>3</issue>
<fpage>410</fpage>
<lpage>415</lpage>
<history>
<date date-type="received">
<day>20</day>
<month>10</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>10</day>
<month>9</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p><italic>Background</italic>: Since the introduction of long-term parenteral nutrition (PN), morbidity due to inadequate replacement or toxicity of routinely administered trace elements has been well described. After decades of experience, much debate still exists about optimal supplementation. In practice, trace elements (TEs) seem to be frequently provided by prescribing an all-inclusive commercial multi-TE admixture with little dosage flexibility. <italic>Aim</italic>: Our goal was to review TE supplementation practice among 5 PN support centers across Canada, through a retrospective review of the Canadian Home PN Registry. <italic>Methods</italic>: Baseline demographic, clinical, and biochemical parameters along with information regarding the PN prescription of 135 patients with complete records were retrieved from the registry database collected between 2005 and 2007. TE supplementation prescriptions were compared with recent guidelines as well as between groups of patients with different PN indications and dietary intake status. Consent was signed by all participating patients. <italic>Results</italic>: The average daily PN concentrations of TE were as follows: zinc, 8.6 ± 5.5 mg (130.92 ± 84.23 µmol); manganese, 452 ± 184 µg (8.22 ± 3.34 µmol); selenium, 78 ± 45 µg (0.99 ± 0.57 µmol); chromium, 11 ± 5 µg (0.21 ± 0.10 µmol); copper, 0.64 ± 0.35 mg (10.11 ± 5.58 µmol); and iodine, 77 ± 42 µg (0.61 ± 0.33 µmol). The mean daily supplementation of zinc, manganese, copper, and selenium exceeded published recommendations. Patients’ underlying anatomy or indication for PN did not significantly influence decisions regarding replacement standards. <italic>Conclusion</italic>: Parenteral TE supplementation in Canadian PN programs needs to be reviewed and adjusted according to most current guidelines. This may require a reevaluation of the commercial TE preparations currently available in Canada and potential new products worldwide to avoid oversupplementation and potential toxicity.</p>
</abstract>
<kwd-group>
<kwd>trace elements</kwd>
<kwd>home parenteral nutrition</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0148607112463074">
<title>Clinical Relevancy Statement</title>
<p>Adequate trace element (TE) supplementation is important for patients on long-term parenteral nutrition (PN). We assessed the practice of TE supplementation from 5 Canadian adult PN programs and compared prescriptions with guidelines, as well as between groups of patients with different needs, to document and evaluate the TE prescription practice across Canada. The results suggest that there is a need for improvement to provide safe and adequate provision of TEs for patients receiving PN.</p>
</sec>
<sec id="section2-0148607112463074" sec-type="intro">
<title>Introduction</title>
<p>A trace element (TE) is defined as a chemical universally present in tissues that is needed in minute quantities for the proper growth, development, and physiology of organisms. TEs can be globally classified into 2 groups: those whose role in human nutrition has been well substantiated and deemed essential (iron, zinc, copper, iodine, fluoride, selenium, chromium, manganese, and molybdenum) and those present in minute amounts that are clearly important in laboratory animals but whose role in human nutrition remains uncertain (cobalt, cadmium, arsenic, silicon, vanadium, nickel, beryllium, uranium, rubidium, and strontium).<sup><xref ref-type="bibr" rid="bibr1-0148607112463074">1</xref></sup></p>
<p>With the implementation of purified crystalline amino acids, the physiologic function of various micronutrients has been appreciated, especially in patients requiring long-term nutrition support. This led to the eventual formulation of guidelines for the routine parenteral supplementation of zinc, copper, manganese, chromium, and, later, selenium.<sup><xref ref-type="bibr" rid="bibr2-0148607112463074">2</xref></sup> After decades of experience in clinical practice, much debate exists around optimal supplementation standards. A heightened sensitivity around TE needs has led to the recognition of potential deficiency and toxicity states, albeit without any drastic change in parenteral nutrition (PN) supplementation guidelines.<sup><xref ref-type="bibr" rid="bibr3-0148607112463074">3</xref></sup> In addition, these recommendations are applicable to healthy adults and not to critically ill patients, in whom decreased serum levels may indicate true deficiency states or deficiency due to redistribution of body stores.<sup><xref ref-type="bibr" rid="bibr4-0148607112463074">4</xref></sup> As discussed by Btaiche et al,<sup><xref ref-type="bibr" rid="bibr5-0148607112463074">5</xref></sup> PN dose adjustments and TE supplementation are generally guided by serum TE concentrations. However, clinical conditions such as short bowel syndrome (SBS), liver disease, and enterocutaneous fistulas can alter TE clearance and diversely affect serum TE concentrations. Benefits of supplementation above and beyond the daily requirements are also unclear. In clinical practice in Canada, a standardized multiple-TE admixture is typically added to PN formulations. Various commercially available preparations exist, but some do not adhere to TE supplementation guidelines (<xref ref-type="table" rid="table1-0148607112463074">Table 1</xref>). This article reviews TE supplementation prescription practice in 5 Canadian adult home PN (HPN) centers participating in the Canadian HPN Registry and compares patient dosages with current guidelines as well as between groups of patients with different needs.</p>
<table-wrap id="table1-0148607112463074" position="float">
<label>Table 1.</label>
<caption><p>Commercial Trace Element Products Available in North America.</p></caption>
<graphic alternate-form-of="table1-0148607112463074" xlink:href="10.1177_0148607112463074-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Parenteral Nutrition Trace Element Products</th>
<th align="center">Volume, mL</th>
<th align="center">Chromium, µg</th>
<th align="center">Copper, mg</th>
<th align="center">Manganese, µg</th>
<th align="center">Selenium, µg</th>
<th align="center">Zinc, mg</th>
<th align="center">Iodine, µg</th>
<th align="center">Molybdenum, µg</th>
</tr>
</thead>
<tbody>
<tr>
<td> MTE-4<sup><xref ref-type="table-fn" rid="table-fn1-0148607112463074">a</xref></sup></td>
<td>1</td>
<td>4</td>
<td>0.4</td>
<td>100</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> MulTE-PAK-4<sup><xref ref-type="table-fn" rid="table-fn2-0148607112463074">b</xref></sup></td>
<td>1</td>
<td>4</td>
<td>0.4</td>
<td>100</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> Multi-TraceElement<sup><xref ref-type="table-fn" rid="table-fn3-0148607112463074">c</xref></sup></td>
<td>1</td>
<td>4</td>
<td>0.4</td>
<td>100</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> MTE-4 Conc<sup><xref ref-type="table-fn" rid="table-fn1-0148607112463074">a</xref></sup></td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>500</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> ConTE-PAK-4<sup><xref ref-type="table-fn" rid="table-fn2-0148607112463074">b</xref></sup></td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>500</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> MultipleTrace Element Conc<sup><xref ref-type="table-fn" rid="table-fn3-0148607112463074">c</xref></sup></td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>500</td>
<td>0</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> MTE5<sup><xref ref-type="table-fn" rid="table-fn1-0148607112463074">a</xref></sup></td>
<td>1</td>
<td>4</td>
<td>0.4</td>
<td>100</td>
<td>20</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> MulTE-PAK-5<sup><xref ref-type="table-fn" rid="table-fn2-0148607112463074">b</xref></sup></td>
<td>1</td>
<td>4</td>
<td>0.4</td>
<td>100</td>
<td>20</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> MultipleTE w/Selenium<sup><xref ref-type="table-fn" rid="table-fn3-0148607112463074">c</xref></sup></td>
<td>1</td>
<td>4</td>
<td>0.4</td>
<td>100</td>
<td>20</td>
<td>1</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> MTE-5 Conc<sup><xref ref-type="table-fn" rid="table-fn1-0148607112463074">a</xref></sup></td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>500</td>
<td>60</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> Multiple TE w/Selenium Conc<sup><xref ref-type="table-fn" rid="table-fn3-0148607112463074">c</xref></sup></td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>500</td>
<td>60</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> Multitrace-5-Conc<sup><xref ref-type="table-fn" rid="table-fn3-0148607112463074">c</xref></sup></td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>500</td>
<td>60</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> MTE-6<sup><xref ref-type="table-fn" rid="table-fn1-0148607112463074">a</xref></sup></td>
<td>1</td>
<td>4</td>
<td>0.4</td>
<td>100</td>
<td>20</td>
<td>1</td>
<td>25</td>
<td>0</td>
</tr>
<tr>
<td> MTE-6 Conc<sup><xref ref-type="table-fn" rid="table-fn1-0148607112463074">a</xref></sup></td>
<td>1</td>
<td>10</td>
<td>1</td>
<td>500</td>
<td>60</td>
<td>5</td>
<td>75</td>
<td>0</td>
</tr>
<tr>
<td> MTE-7<sup><xref ref-type="table-fn" rid="table-fn2-0148607112463074">b</xref></sup></td>
<td>1</td>
<td>4</td>
<td>0.4</td>
<td>100</td>
<td>20</td>
<td>1</td>
<td>25</td>
<td>25</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0148607112463074">
<label>a</label>
<p>American Pharmaceutical Partners (Schaumburg, IL).</p>
</fn>
<fn id="table-fn2-0148607112463074">
<label>b</label>
<p>SoloPak (Boca Raton, FL).</p>
</fn>
<fn id="table-fn3-0148607112463074">
<label>c</label>
<p>American Regent (Shirley, NY).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section3-0148607112463074" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>This was a retrospective review of parenteral TE data from the Canadian HPN Registry, where 143 patients were originally entered between 2005 and 2007. The participating 5 centers were the University Health Network, St Michael’s Hospital, Capital Health Alberta, British Columbia Home PN Program, and the St Boniface Hospital in Winnipeg. These centers usually have one specific company providing supplies and delivering PN solutions. Each center obtained approval from its research ethics board (REB) to enter patient information into the Canadian HPN Registry, and patients consented to be a part of the registry.</p>
<p>At the time of data collection, there were an estimated 400 PN patients/y across Canada,<sup><xref ref-type="bibr" rid="bibr6-0148607112463074">6</xref></sup> which means that the registry had collected more than 25% of HPN patients. The registry is web based and collects information on the following: demographics, anatomy, indications for PN, nutrition assessments (weight, height, body mass index), type of vascular access, parenteral formula prescriptions (including micronutrient concentrations), and complications of PN. These data are initially collected on paper data entry forms and then subsequently entered into the web-based registry. Serum or plasma micronutrient status is recorded when available. However, blood TE measurements are not routinely performed at these centers, and monitoring practices are usually site and health provider dependent. Also, in most provinces, such specialized serum testing is not covered by the provincial government, and patients may not be able to afford or are unwilling to assume the laboratory costs. A complete description of the Canadian HPN Registry has been previously published.<sup><xref ref-type="bibr" rid="bibr6-0148607112463074">6</xref>,<xref ref-type="bibr" rid="bibr7-0148607112463074">7</xref></sup></p>
<sec id="section4-0148607112463074">
<title>Statistical Analysis</title>
<p>Data from the registry were imported into the statistical software program SPSS (SPSS, Inc, an IBM Company, Chicago, IL). Initially, TE prescription information was compared with guidelines and then compared between patients with the presence or absence of SBS, as well as between patients who were NPO (nil per os) vs on an oral/enteral diet. Descriptive statistics were conducted for the total cohort and expressed as mean ± standard deviation (SD) or percentage of population. Preliminary exploratory analysis examined the normality of data. The Wilcoxon–Mann-Whitney test was used to compare differences between groups. SPSS for Windows, version 19.0, was used (SPSS, Inc). A <italic>P</italic> value &lt;.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="section5-0148607112463074" sec-type="results">
<title>Results</title>
<sec id="section6-0148607112463074">
<title>Patients</title>
<p>At the time of analysis, there were 143 patients in the HPN Registry database, from 5 sites. Of these, 135 patients had TE prescription information available. <xref ref-type="table" rid="table2-0148607112463074">Table 2</xref> illustrates the baseline demographics of these 135 patients, which were used for further analyses.</p>
<table-wrap id="table2-0148607112463074" position="float">
<label>Table 2.</label>
<caption><p>Baseline Characteristics.</p></caption>
<graphic alternate-form-of="table2-0148607112463074" xlink:href="10.1177_0148607112463074-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Characteristic</th>
<th align="center">Mean ± SD or No. (%) of Study Population (N = 135)</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="2"><italic>Patient data</italic></td>
</tr>
<tr>
<td> Age, y</td>
<td>53.5 ± 13.7</td>
</tr>
<tr>
<td> Month on PN<sup><xref ref-type="table-fn" rid="table-fn5-0148607112463074">a</xref></sup></td>
<td>74.1 ± 79.5 (median [range<sup><xref ref-type="table-fn" rid="table-fn6-0148607112463074">b</xref></sup>]: 44.0 [1,396])</td>
</tr>
<tr>
<td> BMI before PN</td>
<td>19.2 ± 4.5</td>
</tr>
<tr>
<td colspan="2">Sex</td>
</tr>
<tr>
<td> Male</td>
<td>51 (37.8)</td>
</tr>
<tr>
<td> Female</td>
<td>82 (60.7)</td>
</tr>
<tr>
<td> Missing</td>
<td>2 (1.5)</td>
</tr>
<tr>
<td colspan="2">Reasons for PN<sup><xref ref-type="table-fn" rid="table-fn7-0148607112463074">c</xref></sup></td>
</tr>
<tr>
<td> SBS</td>
<td>88 (65.2)</td>
</tr>
<tr>
<td> Mucosal defect</td>
<td>12 (8.9)</td>
</tr>
<tr>
<td> Motility disorder</td>
<td>20 (14.8)</td>
</tr>
<tr>
<td> Cancer</td>
<td>22 (16.3)</td>
</tr>
<tr>
<td> Surgical complications</td>
<td>18 (13.3)</td>
</tr>
<tr>
<td> Pancreatic disorder</td>
<td>3 (2.2)</td>
</tr>
<tr>
<td> No reason indicated</td>
<td>5 (3.7)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0148607112463074">
<p>BMI, body mass index; PN, parenteral nutrition; SBS, short bowel syndrome.</p>
</fn>
<fn id="table-fn5-0148607112463074">
<label>a</label>
<p>Number of months on PN is calculated from start of PN support to end date of PN or if PN has not ended to the date of data extraction.</p>
</fn>
<fn id="table-fn6-0148607112463074">
<label>b</label>
<p>The range is the lowest (min) and highest (max) number of months on PN to show the statistical dispersion.</p>
</fn>
<fn id="table-fn7-0148607112463074">
<label>c</label>
<p>Some patients have multiple indications for PN.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section7-0148607112463074">
<title>TE Provision in PN</title>
<p>The average reported PN supplementation of TEs across the 5 PN centers and comparisons with published American Medical Association (AMA)<sup><xref ref-type="bibr" rid="bibr2-0148607112463074">2</xref></sup> and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)<sup><xref ref-type="bibr" rid="bibr3-0148607112463074">3</xref></sup> guidelines are featured in <xref ref-type="table" rid="table3-0148607112463074">Table 3</xref>. Zinc supplementation exceeded both published recommendations. Manganese and copper provision exceeded the A.S.P.E.N. but not the older AMA recommendations. Selenium supplementation exceeded the only published recommendations by A.S.P.E.N. in 2002. There are no specific guidelines for iodine provision, although the daily requirements in adult patients receiving total enteral nutrition (EN) or PN are estimated to be between 0.55 and 1.18 µmol.<sup><xref ref-type="bibr" rid="bibr8-0148607112463074">8</xref></sup></p>
<table-wrap id="table3-0148607112463074" position="float">
<label>Table 3.</label>
<caption><p>Average Daily Trace Element Supplementation Across All HPN Centers in Comparison to Published Guidelines.</p></caption>
<graphic alternate-form-of="table3-0148607112463074" xlink:href="10.1177_0148607112463074-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Micronutrient</th>
<th align="center">Mean ± SD</th>
<th align="center">A.S.P.E.N. Guidelines<sup><xref ref-type="bibr" rid="bibr3-0148607112463074">3</xref></sup></th>
<th align="center">AMA Nutrition Advisory Group Guidelines<sup><xref ref-type="bibr" rid="bibr2-0148607112463074">2</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinc, mg (µmol)</td>
<td>8.6 ± 5.5 (130.92 ± 84.23)</td>
<td>2.5–5.0 (38.75–76.50)</td>
<td>2.5–4.0 (38.75–61.2)</td>
</tr>
<tr>
<td>Manganese, µg (µmol)</td>
<td>452 ± 184 (8.22 ± 3.34)</td>
<td>60–100 (1.09–1.82)</td>
<td>150–800 (2.73–14.56)</td>
</tr>
<tr>
<td>Selenium, µg (µmol)</td>
<td>78 ± 45 (0.99 ± 0.57)</td>
<td>20–60 (0.25–0.76)</td>
<td/>
</tr>
<tr>
<td>Chromium, µg (µmol)</td>
<td>11 ± 5 (0.21 ± 0.10)</td>
<td>10–15 (0.19–0.29)</td>
<td>10–15 (0.19–0.29)</td>
</tr>
<tr>
<td>Copper, mg (µmol)</td>
<td>0.64 ± 0.35 (10.11 ± 5.58)</td>
<td>0.3–0.5 (4.73–7.88)</td>
<td>0.5–1.5 (7.87–23.61)</td>
</tr>
<tr>
<td>Iodine, µg (µmol)</td>
<td>77 ± 42 (0.61 ± 0.33)</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn8-0148607112463074">
<p>AMA, American Medical Association; A.S.P.E.N., American Society for Parenteral and Enteral Nutrition; HPN, home parenteral nutrition.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-0148607112463074">
<title>Comparison of TE Supplementation in Patients With SBS vs Non-SBS</title>
<p>To delineate whether patients’ underlying anatomy or indication for PN influences the amount of supplemented trace additives ordered by physicians, we compared TE concentrations in the formulas of patients with SBS (n = 88) vs non-SBS (n = 42) in <xref ref-type="table" rid="table4-0148607112463074">Table 4</xref>. Five participants were excluded because of missing information on indication for PN. Patients with SBS had severe malabsorption associated with high-output fistulas, ostomy, or significant diarrhea. SBS included causes such as Crohn’s disease, ischemic bowel, and necrotizing enterocolitis.<sup><xref ref-type="bibr" rid="bibr7-0148607112463074">7</xref></sup> Non-SBS included patients who had poor oral intake that may or may not be associated with malabsorption but no significant diarrhea or high-output fistula or ostomy. Causes included mucosal defects such as celiac disease, radiation enteritis, and microvillus inclusion as well as motility disorders such as pseudo-obstruction and Hirschsprung disease; tumors/cancer; or surgical complications such as obstruction and enterocutaneous fistula. Patients with SBS received significantly less selenium and iodine compared with non-SBS patients, but otherwise, there were no significant differences in TE prescription between groups, and the amounts of TE were either above or within recommendations in both groups. We then assessed in each of these groups whether there was a difference in TE prescription between patients who were NPO and those who were on oral and/or EN. In the SBS group, 61 patients (n = 61/88) were on oral and/or EN, and 27 were NPO. In the non-SBS group, 23 patients were on oral and/or EN, whereas 19 were NPO. For both SBS and non-SBS groups, there were no differences in TE prescriptions between NPO patients and those receiving oral and/or EN, except for a slightly higher intake of copper (<xref ref-type="table" rid="table5-0148607112463074">Table 5</xref>) in the non-SBS group on oral/EN vs those who were NPO (<italic>P</italic> = .043).</p>
<table-wrap id="table4-0148607112463074" position="float">
<label>Table 4.</label>
<caption><p>Trace Element Supplementation in HPN Patients With SBS vs Non-SBS.</p></caption>
<graphic alternate-form-of="table4-0148607112463074" xlink:href="10.1177_0148607112463074-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Micronutrient</th>
<th align="center">SBS (n = 88), Mean ± SD, µmol/d</th>
<th align="center">Non-SBS (n = 42), Mean ± SD, µmol/d</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinc</td>
<td>129.72 ± 80.98</td>
<td>138.69 ± 86.48</td>
<td>.453</td>
</tr>
<tr>
<td>Manganese</td>
<td>8.19 ± 2.97</td>
<td>8.73 ± 3.88</td>
<td>.186</td>
</tr>
<tr>
<td>Selenium</td>
<td>0.94 ± 0.54</td>
<td>1.14 ± 0.57</td>
<td>.030<sup><xref ref-type="table-fn" rid="table-fn10-0148607112463074">a</xref></sup></td>
</tr>
<tr>
<td>Chromium</td>
<td>0.20 ± 0.09</td>
<td>0.24 ± 0.09</td>
<td>.077</td>
</tr>
<tr>
<td>Copper</td>
<td>10.38 ± 5.30</td>
<td>9.48 ± 6.29</td>
<td>.343</td>
</tr>
<tr>
<td>Iodine</td>
<td>0.54 ± 0.27</td>
<td>0.68 ± 0.30</td>
<td>.014<sup><xref ref-type="table-fn" rid="table-fn10-0148607112463074">a</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0148607112463074">
<p>HPN, home parenteral nutrition; SBS, short bowel syndrome.</p>
</fn>
<fn id="table-fn10-0148607112463074">
<label>a</label>
<p>Statistically significant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table5-0148607112463074" position="float">
<label>Table 5.</label>
<caption><p>Comparison of Trace Element Supplementation in HPN Patients With or Without Oral/Enteral Intake.</p></caption>
<graphic alternate-form-of="table5-0148607112463074" xlink:href="10.1177_0148607112463074-table5.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center" colspan="3">SBS<hr/></th>
<th align="center" colspan="3">Non-SBS<hr/></th>
</tr>
<tr>
<th align="left">Micronutrient</th>
<th align="center">NPO (n = 27), Mean ± SD, µmol/d</th>
<th align="center">Oral ± Enteral (n = 61), Mean ± SD, µmol/d</th>
<th align="center"><italic>P</italic> Value</th>
<th align="center">NPO (n = 19), Mean ± SD, µmol/d</th>
<th align="center">Oral ± Enteral (n = 23), Mean ± SD, µmol/d</th>
<th align="center"><italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zinc</td>
<td>145.97 ± 78.58</td>
<td>122.41 ± 81.62</td>
<td>.271</td>
<td>118.80 ± 83.44</td>
<td>155.13 ± 87.27</td>
<td>.160</td>
</tr>
<tr>
<td>Manganese</td>
<td>8.32 ± 3.37</td>
<td>8.13 ± 2.80</td>
<td>.847</td>
<td>8.64 ± 4.70</td>
<td>8.81 ± 3.16</td>
<td>.814</td>
</tr>
<tr>
<td>Selenium</td>
<td>0.85 ± 0.43</td>
<td>0.98 ± 0.58</td>
<td>.675</td>
<td>0.93 ± 0.43</td>
<td>1.31 ± 0.63</td>
<td>.120</td>
</tr>
<tr>
<td>Chromium</td>
<td>0.21 ± 0.11</td>
<td>0.20 ± 0.09</td>
<td>.503</td>
<td>0.23 ± 0.10</td>
<td>0.24 ± 0.08</td>
<td>.320</td>
</tr>
<tr>
<td>Copper</td>
<td>10.60 ± 5.38</td>
<td>10.28 ± 5.31</td>
<td>.826</td>
<td>8.05 ± 6.37</td>
<td>10.67 ± 6.11</td>
<td>.043<sup><xref ref-type="table-fn" rid="table-fn12-0148607112463074">a</xref></sup></td>
</tr>
<tr>
<td>Iodine</td>
<td>0.56 ± 0.30</td>
<td>0.53 ± 0.25</td>
<td>.566</td>
<td>0.71 ± 0.40</td>
<td>0.66 ± 0.19</td>
<td>.110</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0148607112463074">
<p>HPN, home parenteral nutrition; NPO, nil per os; SBS, short bowel syndrome.</p>
</fn>
<fn id="table-fn12-0148607112463074">
<label>a</label>
<p>Statistically significant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section9-0148607112463074" sec-type="discussion">
<title>Discussion</title>
<p>Since the advent of long-term PN for patients with intestinal failure, morbidity due to inadequate or excessive replacement of micronutrients has been well described.<sup><xref ref-type="bibr" rid="bibr9-0148607112463074">9</xref><xref ref-type="bibr" rid="bibr10-0148607112463074"/>-<xref ref-type="bibr" rid="bibr11-0148607112463074">11</xref></sup> Intestinal absorption has a significant role in the homeostasis of TE physiologic levels, and thus, their supplementation by the parenteral route bypasses this important regulatory feedback mechanism and makes the patient susceptible to the complications of oversupplementation. However, TE requirements for this patient population are not well understood, and there is increasing concern that fixed-dose multi-TE commercial formulations for adult patients on long-term PN, especially if administered for more than 30 days, may lead to toxicity from chronic oversupplementation.<sup><xref ref-type="bibr" rid="bibr12-0148607112463074">12</xref><xref ref-type="bibr" rid="bibr13-0148607112463074"/><xref ref-type="bibr" rid="bibr14-0148607112463074"/><xref ref-type="bibr" rid="bibr15-0148607112463074"/><xref ref-type="bibr" rid="bibr16-0148607112463074"/><xref ref-type="bibr" rid="bibr17-0148607112463074"/><xref ref-type="bibr" rid="bibr18-0148607112463074"/><xref ref-type="bibr" rid="bibr19-0148607112463074"/>-<xref ref-type="bibr" rid="bibr20-0148607112463074">20</xref></sup> As discussed by Btaiche et al,<sup><xref ref-type="bibr" rid="bibr5-0148607112463074">5</xref></sup> TE requirements in PN are challenging due to the poor correlation of serum TE concentrations with tissue stores and the various clinical conditions that can affect TE balance. In Canada, the fixed-dose parenteral multi-TE formulation that is based on the old AMA guidelines continues to be used in PN despite its provision of excessive copper and manganese. Furthermore, the effects of TE dosing based on the A.S.P.E.N. TE dosing guidelines on serum TE concentrations have not been tested in patients receiving long-term HPN.</p>
<p>The goal of our study was to survey the current Canadian practice in TE provision via parenteral formulations through a retrospective review of the first set of TE registry data collected between 2005 and 2007. Our goal was to assess current supplementation standards, compare them with old and newer guidelines, and assess for any areas of improvement and, perhaps, nationwide standardization. The average nationwide daily zinc supplementation (8.6 ± 5.5 mg) exceeded both AMA and A.S.P.E.N. recommendations. This is not surprising as a number of our patients do struggle with high gastrointestinal losses such as SBS. In stable patients without abnormal gastrointestinal losses, recommended requirements are between 3 and 4 mg/d. However, this increases in patients with significant gastrointestinal losses, in whom 12 mg zinc should be added per liter of losses.<sup><xref ref-type="bibr" rid="bibr21-0148607112463074">21</xref></sup> This is important since zinc plays a significant role in immune function and wound healing. In patients with burns, large amounts of zinc supplementation have been shown to reduce the rate of infections. Up to 36 mg/d has been added and shown benefit without toxicity.<sup><xref ref-type="bibr" rid="bibr21-0148607112463074">21</xref></sup></p>
<p>Selenium supplementation exceeded the only published recommendations by A.S.P.E.N. in 2002. Selenium deficiency during PN support has been well described. Reports of reversible cardiomyopathy, skeletal muscle myopathy, abnormalities in nails and hair, and macrocytic anemia have been linked to inadvertent omission of selenium from PN.<sup><xref ref-type="bibr" rid="bibr22-0148607112463074">22</xref><xref ref-type="bibr" rid="bibr23-0148607112463074"/><xref ref-type="bibr" rid="bibr24-0148607112463074"/>-<xref ref-type="bibr" rid="bibr25-0148607112463074">25</xref></sup> Therefore, supplementation is important. The potential for toxicity is very low. From studies in geographic regions of selenosis, a tolerable upper intake level of 400 µg/d was identified as the threshold below which no significant adverse effects were reported.<sup><xref ref-type="bibr" rid="bibr26-0148607112463074">26</xref></sup></p>
<p>Manganese and copper daily provisions (452 ± 184 µg and 0.64 ± 0.35 mg, respectively) exceeded the A.S.P.E.N. but not the older AMA recommendations. For manganese supplementation, as discussed by Hardy,<sup><xref ref-type="bibr" rid="bibr27-0148607112463074">27</xref></sup> the optimal dosage for long-term supplementation for adults is likely to be no more than 1 µmol/d (55 µg/d). This recommendation also can be regarded as a maximum dosage for the critically ill and others on short-term PN (5–10 days) in whom contamination and manganese accumulation is less of an issue. In the late 1990s, multiple reports of neurotoxicity from excessive manganese supplementation were published in children and adults.<sup><xref ref-type="bibr" rid="bibr13-0148607112463074">13</xref><xref ref-type="bibr" rid="bibr14-0148607112463074"/><xref ref-type="bibr" rid="bibr15-0148607112463074"/><xref ref-type="bibr" rid="bibr16-0148607112463074"/><xref ref-type="bibr" rid="bibr17-0148607112463074"/><xref ref-type="bibr" rid="bibr18-0148607112463074"/>-<xref ref-type="bibr" rid="bibr19-0148607112463074">19</xref></sup> More recently, manganese deposits in the basal ganglia, causing neurological toxicity, have been shown on magnetic resonance imaging (MRI) of HPN patients with elevated serum manganese concentrations.<sup><xref ref-type="bibr" rid="bibr28-0148607112463074">28</xref></sup> A recent postmortem study from autopsy specimens of 8 long-term PN patients who were supplemented with micronutrients according to the AMA 1979 guidelines did confirm very high concentrations of hepatic copper, manganese, and chromium.<sup><xref ref-type="bibr" rid="bibr20-0148607112463074">20</xref></sup> In patients with hepatic dysfunction from various etiologies, including PN-associated cholestasis, it has been the practice to withhold manganese, copper, and iron additives to prevent hepatic accumulation because of suboptimal biliary secretion.</p>
<p>For copper supplementation, in patients with cholestasis (defined as elevation of the alkaline phosphatase level), a smaller amount of infused copper averaging 0.15 mg/d appeared to be the right dose.<sup><xref ref-type="bibr" rid="bibr29-0148607112463074">29</xref></sup> Patients with diarrhea had increased copper losses and required on average 0.4–0.5 mg/d to maintain balance.<sup><xref ref-type="bibr" rid="bibr29-0148607112463074">29</xref></sup> Selenium, chromium, and iodine excretion is mainly through the urine, although selenium is present in low concentrations in bile as well.<sup><xref ref-type="bibr" rid="bibr30-0148607112463074">30</xref></sup> In the case of chromium, although our long-term PN patients met the guidelines, the long-term use of multiple TE products at recommended doses has been associated with excessive serum concentrations of chromium.<sup><xref ref-type="bibr" rid="bibr31-0148607112463074">31</xref></sup> More recently, Howard et al<sup><xref ref-type="bibr" rid="bibr20-0148607112463074">20</xref></sup> suggested decreasing the daily amount of chromium to 5–10 µg in adults. As discussed by Btaiche et al,<sup><xref ref-type="bibr" rid="bibr5-0148607112463074">5</xref></sup> in long-term PN patients, supplemental chromium may not be necessary, and chromium supplementation based on A.S.P.E.N.’s guidelines may be excessive, considering the significant chromium contam- ination of PN solutions. For iodine, as discussed by Zimmermann,<sup><xref ref-type="bibr" rid="bibr32-0148607112463074">32</xref></sup> many experts do not recommend supplemental iodine for PN patients as PN solutions may contain as much as 15–25 µg iodine as contaminant. Also, many long-term PN patients are able to eat and drink a limited amount and have a functioning duodenum. Thus, they are able to absorb dietary iodine.</p>
<p>Our results also suggest that patients’ underlying anatomy and indication for PN or oral/enteral intake did not significantly influence decisions regarding TE supplementation. TE did not seem to have been adjusted based on oral intake or anatomy, likely due to the use of a commercial preparation, limiting flexibility in dosages. Clearly, there is a need to tailor TE based on published guidelines and/or consensus recommendations. As discussed by Btaiche et al,<sup><xref ref-type="bibr" rid="bibr5-0148607112463074">5</xref></sup> interindividual variations may exist and warrants the use of individualized TE products. The frequency of monitoring TE status in long-term HPN in Canada has not been well documented and has been mostly dependent on individual clinical practice and coverage of laboratory work. Therefore, guidelines and standards for regular monitoring of TE status should be implemented to improve the safety and efficacy of PN therapy. Although it may not be possible to completely eliminate TE contaminants from parenteral products, we should also consider requiring manufacturers to specify the maximum safe or allowable TE contamination limits in parenteral products. As discussed by Buchman et al<sup><xref ref-type="bibr" rid="bibr33-0148607112463074">33</xref></sup> with respect to the United States, it is equally important in Canada for research to lead to the availability of safer commercial products.</p>
<p>There are several limitations of our study. This is a retrospective study, and it does not report on serum TE levels. Although this study is from 2005–2007, the commercially available TE mixes and providers have not changed in Canada. Results are based on data entered in the registry by PN team members who are healthcare professionals responsible for these patients. Although the PN registry was recently validated,<sup><xref ref-type="bibr" rid="bibr7-0148607112463074">7</xref></sup> suggesting that the data collected are reliable, we do lack information on tissue/plasma/whole-blood micronutrient status of individual patients. This is partly because such testing, even though widely available, is not routinely performed in most of our patients for the following reasons: cost constraints, government funding restrictions, questionable reliability for some of the serum markers, and lack of published monitoring guidelines. However, as discussed by Sriram and Lonchyna,<sup><xref ref-type="bibr" rid="bibr34-0148607112463074">34</xref></sup> serum levels must be obtained to avoid toxicity, especially in hepatic and renal insufficiencies, and specific disease states such as burns, fistulas, and long-term support, and therefore there is room for improvement in the way we prescribe and monitor TE. We also lack information on the rationale for individual TE dosing preferences at each center. Each home PN program may have different affiliations with TE manufacturers. Also, the expertise and experience of the health provider, pharmacists, and/or dieticians at each center may play a role.</p>
</sec>
<sec id="section10-0148607112463074" sec-type="conclusions">
<title>Conclusion</title>
<p>Parenteral TE supplementation in Canadian HPN programs needs to be reviewed and adjusted according to the most current guidelines. This may require a reevaluation of the commercial TE preparations currently available in Canada and potential new products worldwide to avoid oversupplementation and potential toxicity. Further research is necessary to better define the safe standards of TE supplementation. The increasing evidence supporting toxicity of various micronutrients, the potential for preexisting cross-contamination, the lack of international standards, and the reluctance of individual tailoring of TE concentrations due to manufacturing pitfalls and costs all highlight the much-needed work to improve the safety and efficacy of TE supplementation in our growing PN population in Canada.</p>
</sec>
</body>
<back>
<ack>
<p><italic>Participating Home PN Programs</italic></p>
<p>Alberta: Edmonton—Dr Leah Gramlich’s team (Holly Ames, RD, MSc; Lisa Heighington, RN; Marie Hancock, RN)</p>
<p>British Columbia: Vancouver—Dr Scott Whittaker’s team</p>
<p>Manitoba: Winnipeg—Dr Donald Duerksen’s team</p>
<p>Ontario: Toronto–St Michael Hospital—Dr K. N. Jeejeebhoy’s team (Clare Meechan, RN; Brian Jurewitsch, PharmD; Fiona Press, RD)</p>
<p>Ontario: Toronto General Hospital—Dr Johane P. Allard’s team (Olivia Saqui, RN; Lydia Fairholm, RD; Mary Baun, BPharm; Mille Yeung, BPharm)</p>
<p>Twenty One Ton, Toronto, Ontario—Andrew Shaw</p>
<p>HTPN Registry sponsors: Calea, Inc and Baxter Corporation</p>
</ack>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: Dr Abdalian received the Canadian Society for Clinical Nutrition (CSCN)-Nestlé Nutrition Fellowship in Clinical Nutrition, and the Canadian HPN registry was funded by Calea Inc. and Baxter Corporation at the time of the project. Dr Allard has been on the advisory board, has been a guest speaker, and has received grants from Calea Inc., Baxter Corp. and Abbott Nutrition. Drs Abdalian, Gramlich, Duerksen, Jeejeebhoy, and Whittaker and Ms. Fernandes have no financial or commercial involvements that might present an appearance of a conflict of interest related to the contribution.</p>
</fn>
<fn fn-type="other">
<p>This article originally appeared online on October 12, 2012.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0148607112463074">
<label>1.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Bowen</surname><given-names>HJM</given-names></name>
</person-group>. <source>Trace Elements in Biochemistry</source>. <edition>2nd ed.</edition> <publisher-loc>New York</publisher-loc>: <publisher-name>Academic Press</publisher-name>.</citation>
</ref>
<ref id="bibr2-0148607112463074">
<label>2.</label>
<citation citation-type="journal">
<collab>American Medical Association</collab>. <article-title>Guidelines for essential trace element preparations for parenteral use: a statement by the Nutrition Advisory Group</article-title>. <source>JAMA</source>. <year>1979</year>; <volume>241</volume>:<fpage>2051</fpage>–<lpage>2054</lpage>.</citation>
</ref>
<ref id="bibr3-0148607112463074">
<label>3.</label>
<citation citation-type="journal">
<collab>American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)</collab>. <article-title>Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2002</year>;<volume>26</volume>(<issue>1</issue>)(<supplement>suppl</supplement>):<fpage>1SA</fpage>–<lpage>138SA</lpage>.</citation>
</ref>
<ref id="bibr4-0148607112463074">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mirtallo</surname><given-names>J</given-names></name>
<name><surname>Canada</surname><given-names>T</given-names></name>
<name><surname>Johnson</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Safe practices for parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2004</year>;<volume>28</volume>(<issue>6</issue>):<fpage>S39</fpage>–<lpage>S70</lpage>.</citation>
</ref>
<ref id="bibr5-0148607112463074">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Btaiche</surname><given-names>IF</given-names></name>
<name><surname>Carver</surname><given-names>PL</given-names></name>
<name><surname>Welch</surname><given-names>KB</given-names></name>
</person-group>. <article-title>Dosing and monitoring of trace elements in long-term home parenteral nutrition patients</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2011</year>;<volume>35</volume>:<fpage>736</fpage>–<lpage>747</lpage>.</citation>
</ref>
<ref id="bibr6-0148607112463074">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raman</surname><given-names>M</given-names></name>
<name><surname>Gramlich</surname><given-names>L</given-names></name>
<name><surname>Whittaker</surname><given-names>S</given-names></name>
<name><surname>Allard</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Canadian home total parenteral nutrition registry: preliminary data on the patient population</article-title>. <source>Can J Gastroenterol</source>. <year>2007</year>;<volume>21</volume>(<issue>10</issue>):<fpage>643</fpage>–<lpage>648</lpage>.</citation>
</ref>
<ref id="bibr7-0148607112463074">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fernandes</surname><given-names>G</given-names></name>
<name><surname>Kaila</surname><given-names>B</given-names></name>
<name><surname>Jeejeebhoy</surname><given-names>KN</given-names></name>
<name><surname>Gramlich</surname><given-names>LM</given-names></name>
<name><surname>Armstrong</surname><given-names>D</given-names></name>
<name><surname>Allard</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Canadian home parenteral nutrition (HPN) registry: validation and patient outcomes</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2012</year>;<volume>36</volume>(<issue>4</issue>):<fpage>407</fpage>–<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr8-0148607112463074">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hassanien</surname><given-names>MH</given-names></name>
<name><surname>Hussein</surname><given-names>LA</given-names></name>
<name><surname>Robinson</surname><given-names>EN</given-names></name>
<name><surname>Preston Mercer</surname><given-names>L</given-names></name>
</person-group>. <article-title>Human iodine requirements determined by the saturation kinetics model</article-title>. <source>J Nutr Biochem</source>. <year>2003</year>;<volume>14</volume>(<issue>5</issue>):<fpage>280</fpage>–<lpage>287</lpage>.</citation>
</ref>
<ref id="bibr9-0148607112463074">
<label>9.</label>
<citation citation-type="journal">
<collab>Keshan Disease Research Group</collab>. <article-title>Observations on effect of sodium selenite in prevention of Keshan disease</article-title>. <source>Chin Med J</source>. <year>1979</year>;<volume>92</volume>:<fpage>471</fpage>–<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr10-0148607112463074">
<label>10.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Shils</surname><given-names>ME</given-names></name>
<name><surname>White</surname><given-names>PL</given-names></name>
</person-group>, eds. <article-title>Working conference on parenteral trace elements</article-title>. <source>Bull N Y Acad Med</source>. <year>1984</year>;<volume>60</volume>:<fpage>115</fpage>–<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr11-0148607112463074">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Greene</surname><given-names>HL</given-names></name>
<name><surname>Hambidge</surname><given-names>KM</given-names></name>
<name><surname>Schanler</surname><given-names>R</given-names></name>
<name><surname>Tsang</surname><given-names>RC</given-names></name>
</person-group>. <article-title>Guidelines for the use of vitamins, trace elements, calcium, magnesium, phosphorus in infants and children receiving total parenteral nutrition</article-title>. <source>Am J Clin Nutr</source>. <year>1988</year>;<volume>48</volume>(<issue>15</issue>):<fpage>324</fpage>–<lpage>1342</lpage>.</citation>
</ref>
<ref id="bibr12-0148607112463074">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moukarzel</surname><given-names>AA</given-names></name>
<name><surname>Song</surname><given-names>MK</given-names></name>
<name><surname>Buchman</surname><given-names>AL</given-names></name>
<etal/>
</person-group>. <article-title>Excessive chromium intake in children receiving total parenteral nutrition</article-title>. <source>Lancet</source>. <year>1992</year>; <volume>339</volume>:<fpage>385</fpage>–<lpage>388</lpage>.</citation>
</ref>
<ref id="bibr13-0148607112463074">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Alves</surname><given-names>G</given-names></name>
<name><surname>Thiebot</surname><given-names>J</given-names></name>
<name><surname>Tracqui</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Neurologic disorders due to brain manganese deposition in a jaundiced patient receiving long-term parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1997</year>;<volume>21</volume>:<fpage>41</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr14-0148607112463074">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fitzgerald</surname><given-names>K</given-names></name>
<name><surname>Mikalunas</surname><given-names>V</given-names></name>
<name><surname>Rubin</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Hypermanganesemia in patients receiving total parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1999</year>;<volume>23</volume>:<fpage>333</fpage>–<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr15-0148607112463074">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mirowitz</surname><given-names>SA</given-names></name>
<name><surname>Westrich</surname><given-names>TJ</given-names></name>
</person-group>. <article-title>Basal ganglial signal intensity alterations: reversal after discontinuation of parenteral manganese administration</article-title>. <source>Radiology</source>. <year>1992</year>;<volume>185</volume>:<fpage>535</fpage>–<lpage>536</lpage>.</citation>
</ref>
<ref id="bibr16-0148607112463074">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hambidge</surname><given-names>KM</given-names></name>
<name><surname>Sokol</surname><given-names>RJ</given-names></name>
<name><surname>Fidanza</surname><given-names>SJ</given-names></name>
<etal/>
</person-group>. <article-title>Plasma manganese concentrations in infants and children receiving parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1989</year>;<volume>13</volume>:<fpage>168</fpage>–<lpage>171</lpage>.</citation>
</ref>
<ref id="bibr17-0148607112463074">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aschner</surname><given-names>JL</given-names></name>
<name><surname>Aschner</surname><given-names>M</given-names></name>
</person-group>. <article-title>Nutritional aspects of manganese homeostasis</article-title>. <source>Mol Aspects Med</source>. <year>2005</year>;<volume>26</volume>(<issue>4-5</issue>):<fpage>353</fpage>–<lpage>362</lpage>.</citation>
</ref>
<ref id="bibr18-0148607112463074">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reynolds</surname><given-names>N</given-names></name>
<name><surname>Blumsohn</surname><given-names>A</given-names></name>
<name><surname>Baxter</surname><given-names>JP</given-names></name>
<name><surname>Houston</surname><given-names>G</given-names></name>
<name><surname>Pennington</surname><given-names>CR</given-names></name>
</person-group>. <article-title>Manganese requirement and toxicity in patients on home parenteral nutrition</article-title>. <source>Clin Nutr</source>. <year>1998</year>;<volume>17</volume>:<fpage>227</fpage>–<lpage>230</lpage>.</citation>
</ref>
<ref id="bibr19-0148607112463074">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fell</surname><given-names>JM</given-names></name>
<name><surname>Reynolds</surname><given-names>AP</given-names></name>
<name><surname>Meadows</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>Manganese toxicity in children receiving long-term parenteral nutrition</article-title>. <source>Lancet</source>. <year>1996</year>;<volume>347</volume>:<fpage>1218</fpage>–<lpage>1221</lpage>.</citation>
</ref>
<ref id="bibr20-0148607112463074">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Howard</surname><given-names>L</given-names></name>
<name><surname>Ashley</surname><given-names>C</given-names></name>
<name><surname>Lyon</surname><given-names>D</given-names></name>
<name><surname>Shenkin</surname><given-names>A</given-names></name>
</person-group>. <article-title>Autopsy tissue trace elements in 8 long-term parenteral nutrition patients who received the current U.S. Food and Drug Administration formulation</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2007</year>;<volume>31</volume>:<fpage>388</fpage>–<lpage>396</lpage>.</citation>
</ref>
<ref id="bibr21-0148607112463074">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jeejeebhoy</surname><given-names>K</given-names></name>
</person-group>. <article-title>Zinc: an essential trace element for parenteral nutrition</article-title>. <source>Gastroenterology</source>. <year>2009</year>;<volume>137</volume>(<issue>5</issue>)(<supplement>suppl</supplement>):<fpage>S7</fpage>–<lpage>S12</lpage>.</citation>
</ref>
<ref id="bibr22-0148607112463074">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van Rij</surname><given-names>AM</given-names></name>
<name><surname>Thomson</surname><given-names>CD</given-names></name>
<name><surname>McKenzie</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. <article-title>Selenium deficiency in total parenteral nutrition</article-title>. <source>Am J Clin Nutr</source>. <year>1979</year>;<volume>32</volume>:<fpage>2076</fpage>–<lpage>2085</lpage>.</citation>
</ref>
<ref id="bibr23-0148607112463074">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brown</surname><given-names>MR</given-names></name>
<name><surname>Cohen</surname><given-names>HJ</given-names></name>
<name><surname>Lyons</surname><given-names>JM</given-names></name>
<etal/>
</person-group>. <article-title>Proximal muscle weakness and selenium deficiency associated with long term parenteral nutrition</article-title>. <source>Am J Clin Nutr</source>. <year>1986</year>;<volume>43</volume>:<fpage>549</fpage>–<lpage>554</lpage>.</citation>
</ref>
<ref id="bibr24-0148607112463074">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kien</surname><given-names>CL</given-names></name>
<name><surname>Ganther</surname><given-names>HE</given-names></name>
</person-group>. <article-title>Manifestations of chronic selenium deficiency in a child receiving total parenteral nutrition</article-title>. <source>Am J Clin Nutr</source>. <year>1983</year>;<volume>37</volume>:<fpage>319</fpage>–<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr25-0148607112463074">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vinton</surname><given-names>NE</given-names></name>
<name><surname>Dahlstrom</surname><given-names>KA</given-names></name>
<name><surname>Strobel</surname><given-names>CT</given-names></name>
<etal/>
</person-group>. <article-title>Macrocytosis and pseudoalbinism: manifestations of selenium deficiency</article-title>. <source>J Pediatr</source>. <year>1987</year>;<volume>111</volume>:<fpage>711</fpage>–<lpage>717</lpage>.</citation>
</ref>
<ref id="bibr26-0148607112463074">
<label>26.</label>
<citation citation-type="book">
<collab>Food and Nutrition Board: Institute of Medicine</collab>. <source>Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>National Academies Press</publisher-name>; <year>2000</year>.</citation>
</ref>
<ref id="bibr27-0148607112463074">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hardy</surname><given-names>G</given-names></name>
</person-group>. <article-title>Manganese in parenteral nutrition: who, when, and why should we supplement?</article-title> <source>Gastroenterology</source>. <year>2009</year>;<volume>137</volume>(<issue>5</issue>)(<supplement>suppl</supplement>):<fpage>S29</fpage>–<lpage>S35</lpage>.</citation>
</ref>
<ref id="bibr28-0148607112463074">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abdalian</surname><given-names>R</given-names></name>
<name><surname>Saqui</surname><given-names>O</given-names></name>
<name><surname>Fernandes</surname><given-names>G</given-names></name>
<name><surname>Allard</surname><given-names>JP</given-names></name>
</person-group>. <article-title>Effects of manganese from a commercial multi-trace element supplement in a population sample of Canadian patients on long-term parenteral nutrition</article-title> [published online July 24, 2012.] <source>JPEN J Parenter Enteral Nutr</source>. doi: <pub-id pub-id-type="doi">10.1177/0148607112454543</pub-id>.</citation>
</ref>
<ref id="bibr29-0148607112463074">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shike</surname><given-names>M</given-names></name>
</person-group>. <article-title>Copper in parenteral nutrition</article-title>. <source>Gastroenterology</source>. <year>2009</year>;<volume>137</volume>(<issue>5</issue>)(<supplement>suppl</supplement>):<fpage>S13</fpage>–<lpage>S17</lpage>.</citation>
</ref>
<ref id="bibr30-0148607112463074">
<label>30.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Alpers</surname><given-names>DH</given-names></name>
<name><surname>Stenson</surname><given-names>WF</given-names></name>
<name><surname>Bier</surname><given-names>DM</given-names></name>
</person-group>. <source>Manual of Nutritional Therapeutics</source>. <edition>4th ed.</edition> <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>.</citation>
</ref>
<ref id="bibr31-0148607112463074">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Moukarzel</surname><given-names>A</given-names></name>
</person-group>. <article-title>Chromium in parenteral nutrition: too little or too much?</article-title> <source>Gastroenterology</source>. <year>2009</year>;<volume>137</volume>(<issue>5</issue>)(<supplement>suppl</supplement>):<fpage>S18</fpage>–<lpage>S28</lpage>.</citation>
</ref>
<ref id="bibr32-0148607112463074">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zimmermann</surname><given-names>MB</given-names></name>
</person-group>. <article-title>Iodine: it’s important in patients that require parenteral nutrition</article-title>. <source>Gastroenterology</source>. <year>2009</year>;<volume>137</volume>(<issue>5</issue>)(<supplement>suppl</supplement>):<fpage>S36</fpage>–<lpage>S46</lpage>.</citation>
</ref>
<ref id="bibr33-0148607112463074">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buchman</surname><given-names>AL</given-names></name>
<name><surname>Howard</surname><given-names>LJ</given-names></name>
<name><surname>Guenter</surname><given-names>P</given-names></name>
<etal/>
</person-group>. <article-title>Micronutrients in parenteral nutrition: too little or too much? The past, present, and recommendations for the future</article-title>. <source>Gastroenterology</source>. <year>2009</year>;<volume>137</volume>(<issue>5</issue>)(<supplement>suppl</supplement>):<fpage>S1</fpage>–<lpage>S6</lpage>.</citation>
</ref>
<ref id="bibr34-0148607112463074">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sriram</surname><given-names>K</given-names></name>
<name><surname>Lonchyna</surname><given-names>VA</given-names></name>
</person-group>. <article-title>Micronutrient supplementation in adult nutrition therapy: practical considerations</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>:<fpage>548</fpage>–<lpage>562</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>